NEW YORK, March 17, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company today announced the closing on March 16th of an Underwritten Public Offering for Seelos Therapeutics, Inc. of 7,500,000 shares of common stock at an offering price of $.60 per share for gross proceeds of $4,500,000. In addition, the Company has granted the underwriters an option to purchase up to an additional 1,125,000 shares of common stock to cover over-allotments.
Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.
The Benchmark Company acted as sole book-running manager of the offering.
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
About The Benchmark Company
The Benchmark Company is a full-service investment banking firm offering a suite of corporate finance, advisory and institutional brokerage services. We were founded in 1988 and are headquartered in New York City with offices in San Francisco, Boston, and Milwaukee. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research and developing institutional sponsorship by leveraging the firm’s sales, trading and equity research capabilities. https://www.benchmarkcompany.com.
